5 results match your criteria: "France. david.klatzmann@sorbonne-universite.fr.[Affiliation]"
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Ann Rheum Dis
December 2022
Sorbonne Université-INSERM UMRS959, Immunology-Immunopathology-Immunotherapy (i3) laboratory, Sorbonne Universite, Paris, France
Objectives: A regulatory T cell (Treg) insufficiency due to shortage of interleukin-2 (IL-2) is central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a multicentre, double-blinded, randomised, placebo-controlled phase II proof-of-concept trial to evaluate the efficacy of low-dose IL-2 therapy in patients with SLE having moderate-to-severe disease activity while receiving standard treatment.
Methods: We randomly assigned 100 patients in a 1:1 ratio to receive either 1.
Impaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice.
Diabetes
April 2021
Sorbonne Universite, INSERM, UMRS959 Immunology-Immunopathology-Immunotherapy Laboratory, Paris, France
Article Synopsis
- Regulatory T cell (Treg) insufficiency in NOD mice leads to the destruction of insulin-producing β-cells by overactive Teffs, resulting in autoimmune diabetes.
- Analysis of TCR repertoires showed that NOD mice had greater Treg and Teff diversity compared to B6 mice, but lacked certain expanded clonotypes found in B6.
- IL-2 treatment in NOD mice restored the expansion of specific amTreg clonotypes, helping prevent diabetes, while having minimal impact on nTregs and Teffs, highlighting a potential therapeutic target for autoimmune diseases.
Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer .
Ann Rheum Dis
December 2021
AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), F-75013, Paris, France, AP-HP, Paris, France
Response to: 'Circulating regulatory T cells were absolutelydecreased in dermatomyositis/polymyositispatients and restored by low-dose IL-2' by Zhang .
Ann Rheum Dis
August 2021
Sorbonne Université - INSERM UMRS959, Sorbonne Unversité, Paris, France
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
Ann Rheum Dis
February 2019
Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Pitié-Salpêtrière Hospital, Paris, France
Objective: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential.
View Article and Find Full Text PDF